GlassScriptPhysician profile
Karli L Moretti
NPI 1598479172
$3,379.35
in general payments reported to CMS, 2019-2025
20 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $321 · 2024: $1,401 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,374 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,374.35 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $660.12 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $602.00 | 2023-2025 | |
| Novo Nordisk INC | $562.07 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $412.65 | 2024-2025 | |
| Lilly USA, LLC | $237.35 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $188.17 | 2024-2025 | Arexvy, Shingrix, Penmenvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.47 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.56 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Verrica Pharmaceuticals INC. | $104.31 | 2024 | Ycanth |
| Ucb, INC. | $83.30 | 2025 | Bimzelx |
| Bayer Healthcare Pharmaceuticals INC. | $50.95 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.10 | 2025 | Vpriv |
| Axsome Therapeutics, INC. | $45.79 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $34.95 | 2025 | Keveyis |
| Almatica Pharma LLC | $31.74 | 2024 | Loreev Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.16 | 2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $19.24 | 2025 | Qelbree |
| Amgen INC. | $18.84 | 2025 | Repatha, Otezla |
| Exact Sciences Corporation | $17.12 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.46 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karli Moretti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.